Minimum Information Model for tolAPC
Names
More detailed information about this field from each metasource.
Minimum Information Model for tolAPC
metasource: Fairsharing.org
version: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
MITAP
metasource: Fairsharing.org
version: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
Names
More detailed information about this field from each metasource.
Minimum Information Model for tolAPC
metasource: Fairsharing.orgversion: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
MITAP
metasource: Fairsharing.orgversion: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
Names
More detailed information about this field from each metasource.
Minimum Information Model for tolAPC
metasource: Fairsharing.orgversion: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
MITAP
metasource: Fairsharing.orgversion: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
The minimum information model for tolAPC (MITAP) guideline is an initiative of members of the tolAPC field to provide a reporting framework that will make differences and similarities between tolAPC products transparent. Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.
Description
More detailed information about this field from each metasource.
The minimum information model for tolAPC (MITAP) guideline is an initiative of members of the tolAPC field to provide a reporting framework that will make differences and similarities between tolAPC products transparent. Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.
metasource: Fairsharing.orgversion: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
Webpage:
https://doi.org/10.7717/peerj.2300Webpage
More detailed information about this field from each metasource.
https://doi.org/10.7717/peerj.2300
metasource: Fairsharing.orgversion: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
Publications:
Publications
More detailed information about this field from each metasource.
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies
PMID: 27635311
metasource: Fairsharing.org
version: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
Publications
More detailed information about this field from each metasource.
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies
PMID: 27635311
metasource: Fairsharing.org
version: FAIRsharing.org: MITAP; Minimum Information Model for tolAPC; DOI: https://doi.org/10.25504/FAIRsharing.zgwrmg; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 03 2022 7:14 p.m.
-
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies
PubMed citations: 26.
26 articles citing: Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. PMID:33958746
Regulatory Cell Therapy in Organ Transplantation: Achievements and Open Questions. PMID:33708227
1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic tolerogenic dendritic cells with specific epigenetic modifications. PMID:33461863
Low-dose 2-deoxy glucose stabilises tolerogenic dendritic cells and generates potent in vivo immunosuppressive effects. PMID:33074350
Treatment With FoxP3+ Antigen-Experienced T Regulatory Cells Arrests Progressive Retinal Damage in a Spontaneous Model of Uveitis. PMID:33013877
Synergistic Effects of Interferon-γ and Vitamin D3 Signaling in Induction of ILT-3highPDL-1high Tolerogenic Dendritic Cells. PMID:31798578
Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis. PMID:31727095
Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models? PMID:31139178
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. PMID:30962374
Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets. PMID:30936876
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective. PMID:30853957
Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy. PMID:30787930
Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation. PMID:29760704
Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice. PMID:29503651
Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic Mimicry. PMID:29491866
Trichinella spiralis Excretory-Secretory Products Induce Tolerogenic Properties in Human Dendritic Cells via Toll-Like Receptors 2 and 4. PMID:29416536
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. PMID:29379498
Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity. PMID:29375543
Monitoring T-Cell Responses in Translational Studies: Optimization of Dye-Based Proliferation Assay for Evaluation of Antigen-Specific Responses. PMID:29312346
Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials. PMID:29250062
Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment. PMID:29163502
Dexamethasone and Monophosphoryl Lipid A Induce a Distinctive Profile on Monocyte-Derived Dendritic Cells through Transcriptional Modulation of Genes Associated With Essential Processes of the Immune Response. PMID:29109727
Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease. PMID:29075262
Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases? PMID:28804903
Treatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features. PMID:27826300
Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1. PMID:27667787
Need help integrating and/or managing biomedical data?